Drug Trial Radar · NCT06787612
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
397
Planned (sponsor's estimate)
Start
May 28, 2025
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
UbamatamabDrug
Administered per the protocol
BevacizumabDrug
Administered per the protocol
CemiplimabDrug
Administered per the protocol
FianlimabDrug
Administered per the protocol
PLDDrug
Administered per the protocol
SarilumabDrug
Administered per the protocol
REGN10597Drug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessmentTime frame: Up to 3 years
Locations
56 sites in 5 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
UC San Diego Health
La Jolla, California · Recruiting
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
Advent Health Cancer Institute
Orlando, Florida · Recruiting
Tampa General Hospital Cancer Institute
Tampa, Florida · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
The University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Norton Cancer Institute, St. Matthews Clinic
Louisville, Kentucky · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
The Ohio State University Comprehensive Cancer Center
Hilliard, Ohio · Recruiting
Providence Cancer Institute
Portland, Oregon · Recruiting
University of Pittsburgh Medical Center, Magee-Womens Hospital
Pittsburgh, Pennsylvania · Recruiting
West Penn Hospital of Allegheny Health Network
Pittsburgh, Pennsylvania · Recruiting
Avera Cancer Institute Sioux Falls
Sioux Falls, South Dakota · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Swedish Cancer Institute
Seattle, Washington · Recruiting
University of Wisconsin
Madison, Wisconsin · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Centre Hospitalier Universitaire (CHU) de Quebec - Universite Laval
Québec, Canada · Recruiting
CancerCare Manitoba
Winnipeg, Manitoba, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Centre de Santé et de Services Sociaux de la Montérégie-Centre
Greenfield Park, Quebec, Canada · Recruiting
Jewish General Hospital
Montreal, Quebec, Canada · Recruiting
Research Institute - McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Keimyung University Dongsan Hospital
Daegu, South Korea · Recruiting
Severance Hospital Yonsei University Health System
Seoul, South Korea · Recruiting
Asan Medical Center, Univ. of Ulsan
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Gangnam Severance Hospital
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Korea University Guro Hospital
Seoul, South Korea · Recruiting
National Cancer Center
Gyeonggi-do, Gyeonggi-do, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Gachon University Gil Medical Center
Incheon, Seoul, South Korea · Recruiting
Chi Mei Medical Center
Tainan, Taiwan · Recruiting
Mackay Memorial Hospital
Taipei, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.